KRAS and non-small cell lung carcinoma: In general, no individual publication was found to be significantly biasing the results (Figure 2C, 2F, 3C, 3F, 4C, 4F and Figure S2A-D), but the associations between KRAS mutation with lower response rate and shorter remission period of chemotherapy in EGFR wild-type NSCLC were affected after the data set of Mihaly [28] was removed (Figure S2E, S2F).